Dr Reddys Laboratories Share Price Today - Live Blog for November 18, 2025

The share price of Dr Reddys Laboratories Ltd plunged by -0.12%, leaving investors concerned. At this moment, the stock can be acquired at ₹1,242.75, but investors are assessing whether this is a temporary dip or a long-term trend.

With a -0.12% decrease, Dr Reddys Laboratories Ltd's share price is currently at ₹1,242.75. This development raises questions about the factors behind the decline. The stock's PE ratio is 18.1000, while the industry PE is 33.4307.

The share price of Dr Reddys Laboratories Ltd has plummeted by -0.07%, signalling a challenging period. Currently trading at ₹1,242.75, this stock has caught the eye of bargain hunters, who may be considering their entry points.

Dr Reddys Laboratories Ltd observed a -0.02% decrease in its share price, a situation that merits attention. As of now, it's actively trading at ₹1,244.00. The stock has a PE ratio of 18.1000, an ROE of 16.0277% and a debt to equity ratio of 0.1625.

The stock of Dr Reddys Laboratories Ltd suffered a -0.01% decline, and it currently trades at ₹1,244.55 per share. Investors are closely monitoring this situation, looking for potential signs of recovery.

Dr Reddys Laboratories Ltd's share price has fallen by -0.04%, presenting both challenges and opportunities for investors. As of now, it's trading at ₹1,245.50, and market participants are assessing the implications. The stock has a PE ratio of 18.1000, an ROE of 16.0277% and a debt to equity ratio of 0.1625.

Dr Reddys Laboratories Ltd experienced a -0.09% downturn in its share price, and it's currently trading at ₹1,245.15. This situation is generating interest among value investors who are evaluating the stock's potential.

Dr Reddys Laboratories Ltd's share price has experienced a notable 0.31% upswing, and it's currently trading at ₹1,246.30 per share. Investors are closely watching this development.

Dr Reddys Laboratories Ltd's share price has fallen by -0.06%, a situation worth noting. At present, the stock is trading at ₹1,241.80. Investors might find this a moment to reassess their positions. The stock's current Price-to-Earnings (PE) ratio stands at 18.1000, while the industry PE ratio is 33.4307.

With a -0.02% decrease, Dr Reddys Laboratories Ltd's share price is now ₹1,241.10. Investors should examine the factors driving this decline. The stock's PE ratio is 18.1000, whereas the industry PE ratio stands at 33.4307.

Dr Reddys Laboratories Ltd's shares experienced a 0.08% uptick, and they are currently valued at ₹1,241.35, making it an attractive choice for investors. The stock has a debt to equity ratio of 0.1625 and an ROE of 16.0277%.

Dr Reddys Laboratories Ltd's stock price surged by 0.08%, reaching the current market value of ₹1,241.15 per share. This surge is a testament to the stock's recent performance.

Following a noteworthy 0.08% increase, Dr Reddys Laboratories Ltd's shares are now trading at ₹1,240.00. When it comes to valuation, this stock has a PE ratio of 18.1000, with the industry PE ratio at 33.4307.

Dr Reddys Laboratories Ltd observed a -0.08% decrease in its share price, a situation that merits attention. As of now, it's actively trading at ₹1,238.50. The stock has a PE ratio of 18.1000, an ROE of 16.0277% and a debt to equity ratio of 0.1625.

Dr Reddys Laboratories Ltd observed a remarkable 0.06% surge in its share price and is presently trading at ₹1,238.70. The increased investor interest is driving this surge.

In the financial arena, Dr Reddys Laboratories Ltd's stock price has increased by 0.20%, with its current market value per share resting at ₹1,238.65. This development highlights the stock's appeal to investors.

In the financial arena, Dr Reddys Laboratories Ltd's stock price has increased by 0.02%, with its current market value per share resting at ₹1,236.20. This development highlights the stock's appeal to investors.

Investors are buzzing as Dr Reddys Laboratories Ltd's share price soared by an impressive 0.09%. At this moment, it's actively trading at ₹1,236.00, presenting an enticing opportunity for those in the market.

Dr Reddys Laboratories Ltd observed a -0.02% decrease in its share price, a situation that merits attention. As of now, it's actively trading at ₹1,235.00. The stock has a PE ratio of 18.1000, an ROE of 16.0277% and a debt to equity ratio of 0.1625.

Dr Reddys Laboratories Ltd's share price has fallen by -0.04%, presenting both challenges and opportunities for investors. As of now, it's trading at ₹1,235.20, and market participants are assessing the implications. The stock has a PE ratio of 18.1000, an ROE of 16.0277% and a debt to equity ratio of 0.1625.

Dr Reddys Laboratories Ltd's share price has dropped by -0.23%, a development that warrants careful analysis. Presently trading at ₹1,235.00, investors are assessing whether this presents an opportunity or a risk.

Dr Reddys Laboratories Ltd witnessed a -0.25% drop in its share price and is currently trading at ₹1,235.00. With the stock's PE at 18.1000 and the industry PE at 33.4307, investors are weighing their options.

Dr Reddys Laboratories Ltd's stock has surged by 0.06%, and it is currently trading at ₹1,237.75. Additionally, the stock maintains a PE ratio of 18.1000, while the industry PE is 33.4307.

Dr Reddys Laboratories Ltd has had quite the run lately, experiencing a substantial 0.17% uptick in its share price. As a result, it's now actively trading at ₹1,237.30 per share, making it an attractive option for investors.

Dr Reddys Laboratories Ltd's shares experienced a 0.03% uptick, and they are currently valued at ₹1,236.40, making it an attractive choice for investors. The stock has a debt to equity ratio of 0.1625 and an ROE of 16.0277%.

Dr Reddys Laboratories Ltd stock price decreased by -0.18%, with the current market value at ₹1,235.95 per share. Investors are assessing the stock's potential for recovery and future growth prospects.

Dr Reddys Laboratories Ltd experienced a -0.16% dip in its share price and is currently trading at ₹1,241.15. The stock has a PE ratio of 18.1000, an ROE of 16.0277% and a debt to equity ratio of 0.1625.